<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 299 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page298.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=299">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 299 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 299</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=299"><img src="../thumb/299.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>262 / 2020-04                                                            Anti-Microbials - 18.12
   et.fatal., anorex., lipodystrophy, periph. neuropathy/ paraesthes,   (S4) SYRUP, 41/20.2.8/0511. 50 mg/5 ml  low.poss.dos.of concom. atorvastat., adopt.addit./alternat.to hormon.
   insomn., somnol., loss of ment. acuity., convuls., pancreatit, ser.  708709-001: 200 ml, R62,81  contracept., hepat.impairm., protease inhibit. cross-resist., monit.lev.
   amylase incr., rhabdomyolys., thrombocytopen., pure red cell ap-  Dosage: In combinat.with other antiretrovir: Adults: 500 or 600 mg/  of concom. phenyt., incr. bleed. in haemophilia type A & B report.,
   las., aplast.anaem., anx., depress., cardiomyop., dyspn., nail/skin   day in 2-3 div.dos. Dos.of &gt;1 000 mg/day in div.dos.has been used.   monit. triglycer./ cholester.prior to & dur.treatm., inflam. respons. to
   & oral mucosa pigmentat, taste disturb., flatul., dyspeps., sweat.,   Dos.in combinat.ther.should follow guideline of the indiv.drug. Childr:   asymptomat./resid. opportunist.infects. (eg mycobacterium avium)
   myopathy, urin.freq., gynaecomast., chest/gen. pain, asthen., cills,   3 mnths-12 yrs: In combinat. with other antiretrovir: 360-480 mg/m 2   req.furth.eval./treatm., elderly.
   influenza-like syndr.        /day in 3-4 div.dos. Max.dos.not to exceed 200 mg 6 hrly.  Drug interactions: Rifampin signific.decr. therapeut. eff., flutica-
   Warnings and special precautions: Pts.esp. obese women with   Prevent.of matern.-foet.transmiss: Pregn. women (over 14   sone propion.plasma conc. signific. incr., sildenafil/tadalafil & va-
   hepatomegaly/hepatit./other risk fact.for liv.dis./hepat.steatos., dis-  wks.gestat.): 500 mg/day (100 mg 5xdly.) until begin.of labour. IV   radenafil conc. incr., St John’s Wort reduc.plasma conc. result. in
   cont.in pts. develop. lab./clin.find. suggest.lact.acidos./ hepatotox.,   admin. dur.lab.& del.at 2 mg/kg bm over 1 hr.follow.by contin.IV in-  loss of therapeut.eff.& resist.to active ingred. or therapeut.class of
   discont.ther.until pancreatit.diagnos. excl. in cases of N&V/abdom.  fus.1 mg/kg/hr.until umbilic.cord clamp. Newborn infts: Start within   protease inhibit., incr. potent. for ser.adverse reacts.with HMG-CoA
   pain/elev.biochem. mark., ren./hepat.impairm., safety & effic.not   12 hrs.of birth until 6 wks.of age: 2 mg/kg 6 hrly. Consid.IV dos. in   reduct. inhibit. metabol.by CYP3A4 pathway, tipranavir reduc. AUC
   est. in pts. with signific.underlying liv.disords./dis., monit. liv.funct.  infts.unable to receiv.oral dos.at 1,5 mg/kg bm over 30 mins.6 hrly.  and C min, AUC incr./prolong. therapeut. & advers.effs.of drugs me-
   in pts.with pre-exist.liv.dysfunct., monit. hepat.funct.for sev.mnths.  Haematologic.toxic.: Dos.reduct./interupt. poss. necess.if Hb lev.  tabol.by CYP3A, lopinavir conc./therapeut.eff.reduc.by meds. that
   aft.discont.in pts. co-infect.with hepatit.B, pts.with chron.hepatit.   falls betw.7,5-9 g/dl OR neutrophil count falls betw.0,75 & 1,0 x10 /L  induc.CYP3A, CYP3A4 inhibit.incr. lopinavir conc., plasma conc.of
                                                           9
   B/C treat.with antiretrovir.ther.are at incr.risk for sev. & potent.fatal   Combin.ther: Dos.adjustm.for either drug to follow guideline of   zidovudine & abacavir potent.reduc., tenofovir conc.incr., efavirenz
   hepat.adverse reacts., eval.for signs of fat redistribut., elderly, op-  indiv.drug.  & nevirapine decr.plasma conc.of other concom. protease inhibit.,
   portunist. infects & other HIV complicat.still poss., ther.not proven   Contraindications: Abnorm.low neutrophil.cell counts (less than   delavirdine incr.lopinavir plasma conc., conc.of indinavir/nelfinavir/
   to prev.HIV transmiss.through sex.cont./ bld. contam., monit.hae-  0,75x10 /litre)/Hb levels (less than 7,5 g/decilitre), concom.stavu-  saquinavir & amprenavir poss. incr., co-admin. ritonavir incr.lopinavir
                                    9
   matolog.paramet., in case of sev.anaem./myelosuppress./pre-exist.  dine & ribavirin, breast feed., safety dur.first trimest. pregn.not est.  AUC & C min., antiarrhythm. amiodarone/ bepridil/system.lidocaine &
   bone marrow compromise where dos.adjustm.may be reqd./ where   Side effects: Freq: Anaem., neutropen., leucopen., N&V, anorex.,   quinidine conc. incr., digox.lev.incr., trazodone conc.incr., bupropion
   discont.of one of the act.necess.use separ. preps., sero-convers to   mylag., asthen., malaise, headache, insomn. Less freq: Thrombo-  plasma lev.decr., vincrist/vinblastin. conc. incr., phenobarb./phenyt./
   HIV+ status may still occ. despite prompt use & recomm.prophylact.   cytopen., pancytopen.with marrow hypoplas., oral mucosa pigmen-  carbamazep.may decr. lopinavir conc., ketoconazole & itraconazole
   dos. must be strictly adher.to, monit.pts.receiv. concom. co-trimoxa-  tat., lact.acidos.in absence of hypox., sev.hepatomegaly with steatos.   ser. conc. incr., voriconazole steady-state AUC decr., clarithromycin/
   zole, avoid concom.high co-trimoxazole dos.in Pneumocystis carinii   incl.fatal., myopathy, nail & skin pigmentat. Unknown: Abdom.pain,   rifabutin AUC incr., atovaquone therapeut.conc.decr., lopinavir. conc.
   pneumon./ toxoplasmos., monit.lev.of concom.phenytoin, monit. ren.  dyspeps., diarrh., flatul., pancreatit., taste pervers., rais. liv.enzym.&   decr.by dexamethasone, felodipine/nifedipine & nicardipine ser.conc.
   funct./haemotolog.paramet.with concom. potent.nephrotox./myelo-  bilirub., fev., chest & gen.pain, chills, flu-like syndr., anx., depress.,   incr., incr.conc.of cyclospor. / tracrolim. & sirolim., methadone plasma
   suppress. agents, consid.concom.prophylact.antimicrob. ther., con-  rash, urticar., prurit., sweat., dyspn., cough, dizzin., paraesth., convuls.,   conc. low., ethinyl estradiol lev.decr.
   com.self-admin.med., concom.IV ganciclovir/ foscarnet/ribavirin &   somnol., ment.acuity loss, urin.freq., gynaecomast.
   stavudine not recomm., safety in pregn.not est., lactat.  Warnings and special precautions: Concom self-admin. meds.,   ANVIRO, Zydus [P/S]
   Interactions: Poss.interacts.with meds.elimin.by act.ren.secret.,   risk of transmiss.not reduc., not a cure, pts.at risk of develop.illn.as-  Valaciclovir
   co-trimoxazole incr.plasma lev., rifampicin decr. AUC of zidovudine,   soc.with immune suppress., lymphoma develop.risk unknown, op-  Indications: Herpes zoster (shingles), recurr. genit. herpes.in im-
   lamuvidine poss. inhib. zalcitabine intracell.phosphorylat., alt. bld.lev.  portunist.infects.poss., monit. haematolog. parameters incl.Hb.lev./  munocompetent pts., prevent.of H.simplex infect.of skin & ano-
   with phenytoin, probenecid incr.mean half-life & AUC of zidovudine,   neutrophil counts, suspend in case of any findings suggest. of lact.   genit.mucous membr., CMV infect.prophylax., CMV dis. prophylax.
   stavudine intracell. phosphorylat. poss.inhib.by zidovudine, incr.incid.   acidos./hepatotoxic., known risk fact.for liv. dis., longt.effs.of in utero/  aft.organ transplant.
   of neutropen.with paracet., cert.agents incl.aspir./ codeine/ morph./  inft.expos. unknown, elderly, imp.ren./hepat.funct., incr. neutropen.   (S4) TABS. 42/20.2.8/0820
   methadone/ indomethac./ ketoprof./ lorazepam/oxazepam/ naprox./   more freq.at high.dos./advanc.HIV dis./ with pre-exist.neutropen./  716508-001: 500 mg, 10, R197,48
   cimetidine/ clofibrate/dapsone/isoprinosine poss. alt. zidovudine me-  anaem./low vit. B 12 lev.& concom.paracet., avoid NNRTI’s aft.re-  716508-002: 500 mg, 30, R592,47
   tabol.by inhib.glucoronidat. /direct. inhibit.hepat.microsom.metabol.  cov. from lact.acidos.,   716508-003: 500 mg, 42, R829,44
   See also MDR page 62.        Interactions: Metabol.inhibit.by meds.prim. elimin. by hepat.me-  Dosage: Adults:
                                                              Herpes zoster: 1 000 mg 3x/dly.
   ADCO-NEVIRAPINE, AI Pharm. Ltd [P/S]  tabol., phenytoin bld.lev.poss. eith.sub-therapeut./tox., poss.incr.  Recurr.genit.herpes: Init within 24 hrs.of S&S onset. 500 mg
   Nevirapine                   toxic. risk with potent nephrotox./myelosuppres.meds., in-vitro an-  2x/day x5 days.
   Indications: In combinat.with at least 2 other antiretrov. agents   tagon with ribavirin/stavudine, probenecid reduc.ren.excret., mod.   Prevent.of recurr.H.Simplex: Immunocomprom. pts: 500 mg
   for HIV-I infect.            incr. in C max  with concom. lamivudine, rifampic.decr.AUC, incr.incid.  2xdly.
   (S4) TABS, 41/20.2.8/0235    of neutropen.with paracet.    CMV infect.& dis.prophylax: Adults: 2 000 mg 4xdly x90 days
   707961-001: 200 mg, 60, R149,50  ALUVIA, Abbvie [P/S] &    poss.extent.in high risk pts. Init. ther. as early as poss. post-transpl.
   Dosage: Adhere strict.to dos.dur.14 day lead-in period to reduc.  Lopinavir 200 mg, ritonavir 50 mg.  Modify dos. accord.to creatin. clear.
   freq.of skin rash. Monit.clinic. chem. incl.LFT prior to & at interv.dur.  Indications: HIV infect.in combinat.with other antiretroviral agents.  Contraindications: Acyclovir hypersens., safety in pregn.& lactat.
   ther. Follow. recomm.dos.& monit.of other concom. antiretrovir.ther.  (S4) TABS, 41/20.2.8/0217  not est., safety in childr.not est.
   Adults: Init 200 mg dly.x14 days (i.e. lead-in period) follow.by 200 mg   710028-001: 112, R308,40  Side effects: GI disturbs., abdom.pain, headache, fatig., CNS effs.
   2xdly.in combinat.with at least two antiretrov.agents to which pt.not   Dosage: Adults: Recomm.dos:  incl.confus.states/psychos.& coma, bld.dyscras., ac.ren.fail., dys-
   prev. expos. to. Tot.dly.dos.not to exceed 400 mg.  Ther.-naïve pts.: 2x 200/50 mg tabs.2xdly. OR 4 x 200/50 mg   menorrh., hepatit., jaund., diffuse hair.loss, hypersens. reacts.incl.
   Contra-indications: Sev.hepat.impairm., Child-Pugh class B or C,   tabs.1xdly.  anaphylax., photosens.
   end-stage ren.fail.when pts. not haemodialys., AST/ALT &gt;5x upper   Ther.-exper.pts.: 2x 200/50 mg tabs.2xdly.  Special precautions: Concom.meds.excret.via ren.tubul.secret.
   lev.of normality (ULN) until baseline AST/ALT stabilis. &lt;5 ULN, not   Paed.pts.with body surf.area great.than 1,3m : Use adult dos.  may compet.with acyclovir for eliminat., elderly, ren.funct.impairm.,
                                                     2
   to be re-introduc.in cases of perman. discont. for sev.rash/rash with   of 2x 200/50 mg tabs.2xdly.  maint.adeq. hydrat.
   constitut. sympts. / hypersens.syndr./clinic.hepatit., AST/ALT&gt; 5x ULN   Concom.efavirenz/nevirapine/amprenavir/ fosamprenavir   Warnings: Thrombocytopen.purpura/haemolyt. uraem. syndr
   dur.ther.& had rapid recurr.of liv.funct. abnormalit.on re-admin., safety   or nelfinavir: Use above recomm. dos.of 2x 200/50 mg tabs.2xdly.  poss.result.in death report.in pts.with advanc.HIV dis.& aft.bone
   in pregn.& lactat. not est., concom.ketoconazole & St. John’s Wort.  See lit.for dos.guidelin.accord.to body surf.area.  marr.& ren.transpl.
   Side effects: Sev.& life threaten.skin reacts. incl.Stev.John.syndr.&   Contraindications: Safety in pregn.& lactat. not est., concom.  Drug interactions: Cimetidine & probenec.decr. ren.excret., plasma
   tox.epiderm.necrolys., hypersens.syndr.charact.by rash with consti-  drugs highly depend.on CYP3A for clear. where elev.plasma conc.  AUC’s of aciclovir & mycophenolate both incr.when admin.concom.
   tut. sympts., sev./life threaten.hepatotox.incl.fatal fulmin.hepatit.,   are assoc.with ser. &/life-threaten.events: midazolam/triazolam/
   somnol., bld.dyscras., allerg. reacts.incl.anaphylax., headache, GI   ergotamine/dihydroergotamine/ ergonovine/ methylergonovine/  ASPEN ACYCLOVIR, (Aspen Pharmacare: Pharma) Phar-
   disturbs., myalg., arthralg., fatig., fev., ren./hepat.dysfunct.  pimozide/cisapride/astemizole/ terfenadine/sildenafil (when used for   macare [P/S]
                   st
   Special precautions: Critic.to monit.1  18 wks. to identify sev.life-  treatm.of PAH), concom.St John’s Wort, concom.rifampicin, concom.   Acyclovir
   threaten.skin reacts./hepatit. or hepat.fail., discont.ther.if sev.rash/  lovastatin/simvastatin not recomm., concom. tipranavir not recomm.,   Indications: Treatm.& prophylax.of H. simplex infects.in immuno-
   rash accompan. by constitut.find.exper., perman. discont. if mod.to   concom. voriconazole not recomm.  comprom.pts., treatm.of Varicella-Zoster infects.in immunocomprom.
   sev.LFT abnorm.detect./ hypersens. syndr.occurs, incr.AST/ALT lev.&/   Side effects: Hyperglycaem., diabet.ketoacidos., pancreatit., di-  pts. (in shingles only if lesions not older than 72 hrs. & use in chick-
   chron. hepatit.B&C co-infect.assoc.with great. risk of hepat.adverse   arrh., bact/viral infect., otit.media, furunculos., sinusit./bronchit., flu   enpox may prev.pneumon.complicat.).
   events dur.antiretrovir.ther. contain.nevirapine, interrupt.ther.in case   syndr., sialadenit., benign skin neoplasm, cyst, bld. dyscras., allerg.  (S4) IV INFUS,  32/20.2.8/0257
   of mod. abnorm.liv.funct.tests & only re-introduc.at init. dos. once   reacts., male hypogonad., Cushings syndr., hypothyroid., avitaminos.,   895014-003: 250 mg, 5 vials, R585,35
   tests return to baseline, resist.virus emerg. with monother.theref.al-  Dosage: Admin.by slow IV infus.only over 1 hr. Durat. of treatm norm
   ways admin.as combinat.ther., careful monit.of pts.with pre-treatm.   dehydrat., incr. appetite, lact.acidos., obesity, anorex., diab. mellit.,   5 days accord.to pts.condit. & respons.
                                weight gain, psych.disords., CNS effs., encephalopathy, fac.paralys.,
   AST/ALT 2-3xULN for deteriorat.of liv. funct., adeq.contracept.other   hyperton., neuropathy, paraesthes., periph.neurit., taste loss /pervers.,   Adults:
   than hormon.in women, women at high.risk of develop.rash, monit.   migraine, dyskines., cerebr.infarct, convuls., abnorm.vis., eye disor-  5 mg/kg 8 hrly.
   liv.funct.prior to & at interv.dur.ther.& vigil. for prodrom.signs of hep-  ds., tinnit., vertigo, palpitat., lung oed., MI, arter.fibrillat., hypertens.,   Varicella-zoster in immunocomprom.pts. with norm. ren.
   atit., opportunist. infects.& other complicat.of HIV infect.may contin.,   thrombophlebit,. varicose vein, vasculit., vasc. disords., postur.hypo-  funct: 10 mg/kg 8 hrly.
   concom.fluconazole, monit.prothromb. time with concom.warfar.as   tens., dyspn., rhinit., cough, other GI disturbs.incl.haemorrhag.colit.,   H.simplex encephalit.with norm.ren.funct: 10 mg/kg 8 hrly.
   coagulat.time may incr./decr., alt.ther.to clarithromycin recom.in My-  mouth ulcerat., pancreatit., stomatit., periodonit., hepatobil. disords.,   x10 days.
   cobacterium avium-intracellular complex., if ther. interrup.for long.  arthralg., arthros., myalg., back pain, joint disord. bone necros., ab-  Childr: 8 hrly dos.calc.by body surf.using 250 mg/m  as equiv.of 5
                                                                                    2
   than 7 days restart with recomm. lead-in dos., supplem.nevirapine   mg/kg and 500 mg/m  for 10 mg/kg. Neonates: 10 mg/kg 8 hrly.
                                                                       2
   dos. follow.each haemodialys.treatm.  norm.ejaculat., breast enlargem., amenorrh., gynaecomast., impot.,   Contra-indications: Safety in pregn.not est., lactat., topic./IM/oral/
                                menorrhag., skin rash, lipodystrophy, alopec., dry skin, eczema, ex-
   Drug interactions: Low.plasma conc.of concom. meds.metabol.by   SC or ophthalmic.admin.
   CYP3A or CYP2B enzymes, saquinavir (hard gelatince caps) & indinavir   foliat.dermatit., maculopapul. rash, nail disord., prurit., seborrh., skin   Side-effects: Loc.reacts., incr.in bld.urea & creatin., ren.impairm.,
                                discolourat., skin ulc., face oed., acne, sweat., skin striae, kidn.calcul.,
   lev. reduc., incr.plasma lev.with ketoconazole, nevirapine expos.incr.  incr.values for liv.enzym., haematolog.changes., rash, N&V, headache,
   with concom.fluconazole, AUC, C max& C minsignific.low.by rifampicin,   urine abnormalit., albuminur., hypercalcinur., hyperuric., nephrit., as-  encephalopath.changes esp.in immunocomprom.
                                then., chest pain, chills, fev., malaise, pain, periph. oed., drug inter-
   rifabutin conc.signific.incr., hypericum perforatum (St John’s Wort)   Special precautions: Ren.impairm., elderly, ren.toxic.risk incr.when
   decr.conc.& result.sub-optimal lev., elev.trough conc.with cimetidine,   act., oed., hypertrophy, Stev. John.syndr., bradyarrhythm., prolong.  pt.poorly hydrat./in exist. ren.impairm./high dos/rapid or bolus inj.,
                                PR interv., redistribut./accumulat.of body fat, incr. total cholester./
   oestrog.lev.of OC’s signific.decr., plasma conc.of methadone decr.  concom. nephrotox.agents incr.ren.impairm.risk.
                                triglycer.conc., immune reconstit. syndr.  Drug interactions: Probenecid blocks ren.clear.
   ADCO-ZIDOVUDINE, AI Pharm Ltd [P/S]  Special precautions: System.corticoster.eff. report. with inhal./in-
   Zidovudine                   tranas.admin.fluticasone & simil. find.poss.with similar glucorticoids,   ASPEN EFAVIRENZ, Aspen Pharmacare: Pharma)
   Indications: Combin.ther.with other anti-retrovir. for HIV infect.in   advers. effs. of concom.sildenafil/ tadalafil & varadenafil poss. incr.,   Pharmacare [P/S]
   adults, childr.& mothers not breast feed.  new onset/exacerbat.of exist.diabet. mellit., pancreatit.hist., concom.  Efavirenz.
   (S4) TABS, 41/20.2.8/0237    antiarrhythm./ digox., warfar.conc.poss.affect.theref.monit. recom.,   Indications: In combinat.with other antiretrovir. Meds. for HIV-1 in-
   707960-001: 300 mg, 60, R165,20  ketoconazole & itraconazole dos.&gt;200 mg/ day not recomm., use   fect.adults, adolesc.& childr. weigh.40 kg and above.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page298.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>&nbsp;&nbsp;&nbsp;<a href="page295.html">295</a>&nbsp;&nbsp;&nbsp;<a href="page296.html">296</a>&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>&nbsp;&nbsp;&nbsp;<a href="page303.html">303</a>&nbsp;&nbsp;&nbsp;<a href="page304.html">304</a>
             </td>
             <td width="35%"><a href="page300.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page300.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
